All In Biotech

Drug Trial Radar · NCT06772623

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Mar 6, 2025

Primary completion

Nov 2027

Study completion Nov 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Non Small Cell Lung Carcinoma
  • c-MET

Interventions

  • Telisotuzumab AdizutecanDrug

    Intravenous (IV) Infusion

  • BudigalimabDrug

    IV Infusion

  • PembrolizumabDrug

    IV Injection

  • PembrolizumabDrug

    IV Infusion

  • CarboplatinDrug

    IV Infusion

  • PemetrexedDrug

    IV Infusion

  • CisplatinDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab AdizutecanTime frame: Up to Approximately 84 Days
  2. Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to Approximately 33 Months
  3. Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 33 Months

Locations

131 sites in 17 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital - Phoenix /ID# 272971

    Phoenix, Arizona · Active not recruiting

  • Providence - St. Jude Medical Center /ID# 271414

    Fullerton, California · Recruiting

  • FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450

    Oxnard, California · Recruiting

  • UCLA - Santa Monica /ID# 271690

    Santa Monica, California · Recruiting

  • University Of Colorado - Anschutz Medical Campus /ID# 269069

    Aurora, Colorado · Recruiting

  • Rocky Mountain Cancer Centers - Lone Tree /ID# 272603

    Lone Tree, Colorado · Recruiting

  • Mayo Clinic Hospital Jacksonville /ID# 275073

    Jacksonville, Florida · Recruiting

  • Mid Florida Hematology And Oncology Center /ID# 273777

    Orange City, Florida · Recruiting

  • Hope And Healing Cancer Services /ID# 276223

    Hinsdale, Illinois · Recruiting

  • Parkview Comprehensive Cancer Center /ID# 271879

    Fort Wayne, Indiana · Recruiting

  • Community Health Network /ID# 273437

    Indianapolis, Indiana · Completed

  • Kansas City Cancer Center /ID# 273679

    Overland Park, Kansas · Recruiting

  • Dana-Farber Cancer Institute /ID# 278417

    Boston, Massachusetts · Recruiting

  • Henry Ford Hospital - Detroit /ID# 271642

    Detroit, Michigan · Recruiting

  • St. Luke'S /ID# 273344

    Duluth, Minnesota · Recruiting

  • Mayo Clinic-Rochester /ID# 274512

    Rochester, Minnesota · Recruiting

  • Astera Cancer Care /ID# 271915

    East Brunswick, New Jersey · Recruiting

  • New York Cancer And Blood Specialists - Shirley /ID# 272547

    Shirley, New York · Recruiting

  • University Hospitals Cleveland Medical Center /ID# 271726

    Cleveland, Ohio · Completed

  • The Mark H Zangmeister Center /ID# 272502

    Columbus, Ohio · Recruiting

  • Spoknwrd Clinical Trials /ID# 273776

    Easton, Pennsylvania · Recruiting

  • Millennium Physicians /ID# 271717

    Houston, Texas · Completed

  • Joe Arrington Cancer Research /ID# 272776

    Lubbock, Texas · Recruiting

  • Huntsman Cancer Institute /ID# 271686

    Salt Lake City, Utah · Recruiting

  • Virgnia Cancer Specialists /ID# 269633

    Leesburg, Virginia · Recruiting

  • Vista Oncology - East Olympia /ID# 275438

    Olympia, Washington · Recruiting

  • Northwest Medical Specialties Tacoma /ID# 270469

    Tacoma, Washington · Recruiting

  • Centro Oncologico Korben /ID# 281460

    Buenos Aires, Argentina · Recruiting

  • Fundacion Respirar /ID# 281039

    Buenos Aires, Argentina · Recruiting

  • Clinca Colon /ID# 281465

    Mar del Plata, Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming /ID# 282704

    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina · Recruiting

  • Blacktown Hospital /ID# 281588

    Blacktown, New South Wales, Australia · Recruiting

  • Townsville University Hospital /ID# 281498

    Townsville, Queensland, Australia · Recruiting

  • Lyell Mcewin Hospital /ID# 281860

    Elizabeth Vale, South Australia, Australia · Recruiting

  • Peninsula University Hospital /ID# 281824

    Frankston, Victoria, Australia · Recruiting

  • Groupe Sante CHC - Clinique du MontLegia /ID# 271760

    Liège, Belgium · Recruiting

  • Jessa Ziekenhuis - Campus Virga Jesse /ID# 268573

    Hasselt, Limburg, Belgium · Recruiting

  • Vitaz /Id# 280187

    Sint-Niklaas, Oost-Vlaanderen, Belgium · Recruiting

  • AZ-Delta. /ID# 272433

    Roeselare, West-Vlaanderen, Belgium · Recruiting

  • Pontificia Universidad Catolica De Chile /ID# 281594

    Santiago, Region Metropolitana Santiago, Chile · Recruiting

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.